Establishment Labs Holdings, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $60.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on the promising data from Establishment Labs Holdings’s Mia Femtech platform. The recent publication in the Aesthetic Surgery Journal highlights the platform’s safety and effectiveness, showing very low complication rates and high satisfaction among both patients and surgeons.
The positive results from the study, including a low reoperation rate and significant patient satisfaction, reinforce the potential of the Mia Femtech platform to support the company’s growth objectives. Jennings also notes that the company’s target of achieving $30M in sales by 2026 for its minimally invasive platform is encouraging, as it demonstrates confidence in the market expansion potential. The ongoing global launch and commercialization strategy for Mia and Preservé further solidify the company’s position in the market, making it a compelling investment opportunity.
Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Boston Scientific, and Medtronic. According to TipRanks, Jennings has an average return of 2.5% and a 47.79% success rate on recommended stocks.
In another report released on October 6, Mizuho Securities also reiterated a Buy rating on the stock with a $70.00 price target.